Cardiac Pathology › Cardiomyopathies

Cardiomyopathies

Notes

Cardiomyopathies

Sections







Overview

Cardiomyopathies are diseases of the heart muscle that can cause mechanical and/or electrical dysfunction.
Can produce heart failure or fatal arrhythmias.

Four key types based on cardiac morphology:
Dilated, Hypertrophic, Restrictive, Arrhythmogenic Right Ventricular Cardiomyopathy

Be aware that some authors specifically exclude cardiac dilation or hypertrophy caused by cardiac disorders such as hypertension or ischemia, but other authors do not make this distinction. For clarity, in this tutorial, we will use the limited definition of cardiomyopathy and exclude, for example, cardiac hypertrophy that occurs as a physiologic response to valvular disease, etc.

Cardiomyopathies are caused by both genetic and non-genetic factors, though, in many cases, underlying causes are not identified.

Diagnosis of cardiomyopathy includes chest x-rays, ECGs, and echocardiograms.

Treatments are focused on addressing the underlying causes, where appropriate, and the management of heart failure and arrhythmias.

Dilated Cardiomyopathies

Dilated Cardiomyopathies are characterized by dilation and contractile impairment; think of a "ballooning" heart, because "dilated" means to become wider or more open.

Gross Morphology:

Dilated cardiomyopathies produce systolic dysfunction with reduced ejection fractions (typically defined as 40 - 45% less than normal).
The dilated heart is characterized by "ballooning" of the left ventricular, which often leads to dilation in the other chambers, as well.
The dilated heart is heavy, and is often described as "baggy" due to contractile impairment.

Wall thickness is often reduced, and functional mitral valve regurgitation is possible (due to sagging and lack of structural support).
Mural thrombi formation is also possible.

Histology:

Hypertrophied cells and loss of myofibrils with interstitial fibrosis in histological samples.

Symptoms:

Left ventricular dilation is associated with dyspnea and fatigue, and that right ventricle dilation can lead to peripheral edema.

Causes:

Dilated cardiomyopathies can be caused by several factors, including:
Genetic mutations, which often lead to defects in the cardiac myocyte cytoskeleton, sarcolemma, and nuclear envelope.
Various infections, including Coxasackievirus, Chagas Disease, and HIV;
Toxins and drugs, especially alcohol abuse, cocaine, and some cancer drugs.
Metabolic disorders, including diabetes, hyper- or hypo-thyroidism, hyper- or hypo-kalemia, and various nutritional deficiencies.
Neuromuscular diseases, such as Friedreich ataxia and muscular dystrophy.
Pregnancy (the cardiomyopathy becomes apparent in late pregnancy or postpartum period).
Myocarditis.

Arrhythmogenic Right Ventricular Cardiomyopathy

Characterized by muscle cell loss with fibrofatty replacement in the wall of the right ventricle.

  • Genetic mutations that cause desmosome defects.
  • Especially likely to cause ventricular arrhythmias.

Hypertrophic Cardiomyopathy

Characterized by hypertrophy, which means that the myocardium grows abnormally thick, (think of a hyper-muscular body builder who can't relax);
Reduced compliance produces diastolic dysfunction.
Ejection fraction is increased or normal; recall that this is a measure of how much blood the left ventricle pumps in a single contraction.
Diastolic filling is impaired (due to reduced compliance), so stroke volume is reduced.

Gross Morphology:

We show a hypertrophic heart with a significantly thickened left ventricular wall and septal myocardium.
The patterns of hypertrophy vary; in some cases, the hypertrophy is asymmetrical and includes only the septum or a portion of the ventricular wall.

In many cases, myocardial hypertrophy leads to obstructive myopathy (HOCM), in which systolic blood flow through the aorta is impaired.
Abnormalities in the mitral valve apparatus (including abnormally positioned papillary muscles and elongated valve leaflets) are associated with systolic anterior motion (SAM), which produces the dynamic left ventricular obstruction, and, possibly, mitral valve regurgitation.

Hypertrophic obstructive cardiomyopathy is often characterized by a systolic ejection murmur as well as abnormal P-wave and septal Q-waves.

Histology:

Myocardial cell hypertrophy and disarray (note the "swirling" pattern, instead of the normal parallel branching pattern), with interstitial and replacement fibrosis.

Symptoms:

Many patients are asymptomatic, but others experience dyspnea, chest pain, and syncope.

Causes:

Almost exclusively caused by genetic mutations, particularly those that cause defects in the sarcomere and those that cause glycogen storage diseases.

Restrictive Cardiomyopathy

Restrictive cardiomyopathy is a rare disorder that causes diastolic dysfunction.
Characterized by rigid, but not hypertrophic, heart walls.
Ejection fraction is normal, but diastolic filling is impaired due to very low compliance (we draw our heart as if its ventricles are comprised of concrete, which has no elasticity!).
The heart walls may be slightly thickened, but not always.

Several causes of restrictive cardiomyopathy include: post-radiation fibrosis, amyloidosis, sarcoidosis, Loeffler endocarditis, endomyocardial fibrosis, and hemochromatosis.

Clinical Cases

Case 1: Cardiomyopathy Precautions

A 14-year-old male patient presents to the clinic with his father for a high school physical. He is an aspiring athlete and would like to try out for track team during his freshman year. The patient describes that in preparation for his try out, he has been running laps around his neighborhood. He states that he experiences shortness of breath and has to slow down. The patient expresses frustration because slowing down in order to catch his breath has increased the time he takes to complete a mile. He has no past medical history and is not taking any medications. The patient's family history includes hypertension in his father and diabetes in his mother.

His blood pressure is 145/90 mmHg and heart rate 90/min. A 4th heart sound is audible on auscultation. An echocardiogram shows a septum that measures 1.5 cm (normal range: 0.6-1.1 cm).

What should you advise this patient?

  • Refrain from intense exercises and competitive training
  • Hydrate frequently
  • Avoid the use of diuretics
  • All of the above

Answer

  • All of the above

Explanation

All of the answer choices are correct in this scenario because the patient is showing signs and symptoms of hypertrophic cardiomyopathy. Hypertension, exertional shortness of breath, a 4th heart sound, and a thickened septum are among the few that indicate that this patient has hypertrophic cardiomyopathy. This condition can be asymptomatic for years and suddenly manifest with symptoms such as the ones seen in this case.

Hypertrophic cardiomyopathy is the second most common cause of death in young and healthy athletes in the United States. It is imperative to educate patients on the condition as well as how to manage it. Intense training is found to worsen symptoms such as shortness of breath seen in this patient because of the impaired ejection of blood flow from the septum, which is thickened. The interventricular septum is normally measures between 0.6 cm to 1.1 cm. This patient's septum measure 1.5 cm, which is larger than normal. Additionally, dehydration and the use of diuretics have been found to exacerbate symptoms of hypertrophic cardiomyopathy. Therefore, the patient must be counseled on how to manage this condition.

Board Review

Cardiomyopathies

Getting ready for boards? Review these concise, bulleted high yield reviews for your exam.

USMLE & COMLEX-USA

Nurse Practitioner (NP)

Physician Assistant (PA)

Internal Medicine (ABIM)

References

  • Arany, Zolt, and Uri Elkayam. "Peripartum Cardiomyopathy." Circulation, April 2016. https://doi.org/10.1161/CIRCULATIONAHA.115.020491.
  • Austin, S. L., A. D. Proia, M. J. Spencer-Manzon, J. Butany, S. B. Wechsler, and P. S. Kishnani. "Cardiac Pathology in Glycogen Storage Disease Type III." JIMD Reports 6 (January 31, 2012): 65–72. https://doi.org/10.1007/8904_2011_118.
  • Burke, Michael A., Stuart A. Cook, Jonathan G. Seidman, and Christine E. Seidman. "Clinical and Mechanistic Insights Into the Genetics of Cardiomyopathy." Journal of the American College of Cardiology 68, no. 25 (December 2016): 2871–86. https://doi.org/10.1016/j.jacc.2016.08.079.
  • Corrado, Domenico, Cristina Basso, and Daniel P. Judge. "Arrhythmogenic Cardiomyopathy." Circulation Research, September 2017. https://doi.org/10.1161/CIRCRESAHA.117.309345.
  • Corrado, Domenico, Mark S. Link, and Hugh Calkins. "Arrhythmogenic Right Ventricular Cardiomyopathy." Review-article. http://dx.doi.org.proxy.medlib.uits.iu.edu/10.1056/NEJMra1509267, January 4, 2017. https://doi.org/10.1056/NEJMra1509267.
  • Davies, M J. "CARDIOMYOPATHY: The Cardiomyopathies: An Overview." Heart 83, no. 4 (April 1, 2000): 469–74. https://doi.org/10.1136/heart.83.4.469.
  • "Dilated Cardiomyopathy Management and Treatment." Cleveland Clinic. Accessed June 17, 2019. https://my.clevelandclinic.org/health/diseases/16932-dilated-cardiomyopathy/management-and-treatment.
  • "Drugs for Heart Failure - Cardiovascular Disorders." Merck Manuals Professional Edition. Accessed June 17, 2019. https://www.merckmanuals.com/professional/cardiovascular-disorders/heart-failure/drugs-for-heart-failure.
  • El-Hattab, Ayman W., and Fernando Scaglia. "Mitochondrial Cardiomyopathies." Frontiers in Cardiovascular Medicine 3 (2016). https://doi.org/10.3389/fcvm.2016.00025.
  • Gilbert-Barness, Enid. "Metabolic Cardiomyopathy and Conduction System Defects in Children." Annals of Clinical & Laboratory Science 34, no. 1 (January 1, 2004): 15–34.
    "Heart Failure (HF) - Cardiovascular Disorders." Merck Manuals Professional Edition. Accessed June 17, 2019. https://www.merckmanuals.com/professional/cardiovascular-disorders/heart-failure/heart-failure-hf.
  • Hershberger, Ray E., and Ana Morales. "Dilated Cardiomyopathy Overview." In GeneReviews®, edited by Margaret P. Adam, Holly H. Ardinger, Roberta A. Pagon, Stephanie E. Wallace, Lora JH Bean, Karen Stephens, and Anne Amemiya. Seattle (WA): University of Washington, Seattle, 1993. http://www.ncbi.nlm.nih.gov/books/NBK1309/.
  • Hilfiker-Kleiner, Denise, Arash Haghikia, Justus Nonhoff, and Johann Bauersachs. "Peripartum Cardiomyopathy: Current Management and Future Perspectives." European Heart Journal 36, no. 18 (May 7, 2015): 1090–97. https://doi.org/10.1093/eurheartj/ehv009.
  • Japp, Alan G., Ankur Gulati, Stuart A. Cook, Martin R. Cowie, and Sanjay K. Prasad. "The Diagnosis and Evaluation of Dilated Cardiomyopathy." Journal of the American College of Cardiology 67, no. 25 (June 2016): 2996–3010. https://doi.org/10.1016/j.jacc.2016.03.590.
  • Jia, Guanghong, Vincent G. DeMarco, and James R. Sowers. "Insulin Resistance and Hyperinsulinaemia in Diabetic Cardiomyopathy." Nature Reviews. Endocrinology 12, no. 3 (March 2016): 144–53. https://doi.org/10.1038/nrendo.2015.216.
  • Jia, Guanghong, Michael A. Hill, and James R. Sowers. "Diabetic Cardiomyopathy." Circulation Research, February 2018. https://doi.org/10.1161/CIRCRESAHA.117.311586.
    "Left Ventricular Noncompaction Cardiomyopathy." Heart Failure in the Child and Young Adult, January 1, 2018, 269–90. https://doi.org/10.1016/B978-0-12-802393-8.00020-X.
  • Mahmaljy, Hadi, and Mayank Singhal. "Dilated Cardiomyopathy." In StatPearls. Treasure Island (FL): StatPearls Publishing, 2019. http://www.ncbi.nlm.nih.gov/books/NBK441911/.
  • Marian, Ali J., and Eugene Braunwald. "Hypertrophic Cardiomyopathy." Circulation Research, September 2017. https://doi.org/10.1161/CIRCRESAHA.117.311059.
  • Maron, Barry J. "Clinical Course and Management of Hypertrophic Cardiomyopathy." New England Journal of Medicine 379, no. 7 (August 16, 2018): 655–68. https://doi.org/10.1056/NEJMra1710575.
  • McNally, Elizabeth M., and Luisa Mestroni. "Dilated Cardiomyopathy." Circulation Research, September 2017. https://doi.org/10.1161/CIRCRESAHA.116.309396.
  • "Overview of Cardiomyopathies - Cardiovascular Disorders." Merck Manuals Professional Edition. Accessed June 13, 2019. https://www.merckmanuals.com/professional/cardiovascular-disorders/cardiomyopathies/overview-of-cardiomyopathies.
  • "Restrictive Cardiomyopathy | Circulation Research." Accessed June 18, 2019. https://www-ahajournals-org.proxy.medlib.uits.iu.edu/doi/full/10.1161/CIRCRESAHA.117.310982.
  • Seferovi?, Petar M., and Walter J. Paulus. "Clinical Diabetic Cardiomyopathy: A Two-Faced Disease with Restrictive and Dilated Phenotypes." European Heart Journal 36, no. 27 (July 14, 2015): 1718–27. https://doi.org/10.1093/eurheartj/ehv134.
  • Semsarian, Christopher, Jodie Ingles, Martin S. Maron, and Barry J. Maron. "New Perspectives on the Prevalence of Hypertrophic Cardiomyopathy." Journal of the American College of Cardiology 65, no. 12 (March 2015): 1249–54. https://doi.org/10.1016/j.jacc.2015.01.019.
  • Veselka, Josef, Nandan S Anavekar, and Philippe Charron. "Hypertrophic Obstructive Cardiomyopathy." The Lancet 389, no. 10075 (March 2017): 1253–67. https://doi.org/10.1016/S0140-6736(16)31321-6.